Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
Recruiting · NCT06414135 · Registry updated 2024-08-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, skin disorder, systemic sclerosis | Recruiting | Phase 1 | 2024-08-15 | NCT06414135 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Liangjing Lu | 1 |
| Shanghai Ming Ju Biotechnology Co., Ltd. | 7 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Renji Hospital, Shanghai Jiaotong University School of Medicine | Shanghai | China | 6 |